Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone

Trial Profile

Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs AIC 284 (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 26 May 2009 ClinicalTrials.gov has reported actual end date (Mar 2005) added and actual patient number (82) added.
    • 26 May 2009 ClinicalTrials.gov has reported actual end date (Mar 2005) added and actual patient number (82) added.
    • 26 May 2009 Additional location identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top